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Abstract The present investigation, performed in 1,122
consecutive STEMI patients treated with primary coronary
intervention, was aimed at evaluating: (1) the prevalence of
prior anemia and its prognostic significance in the short
term; and (2) the prevalence of new anemia and its impact
in the short term. The prevalence of prior anemia was
27.4%. Patients with a prior anemia were older and
exhibited a higher incidence of chronic diseases and
comorbidities. They showed a higher intra-hospital mor-
tality rate (p \ 0.001), a higher incidence of PCI failure
(p \ 0.001) and major bleedings (p \ 0.001). Prior anemia
was an independent predictor for intra-hospital mortality
(OR 2.12; 95% CI 1.21–3.70, p = 0.009). Patients with a
new anemia account for 46.8% of our series, and showed a
higher early mortality rate and incidence of major bleed-
ings in respect to those who maintained normal Hb values
(p \ 0.05 and \0.05, respectively). our data strengthens
the prognostic role of Hb values in STEMI patients sub-
mitted to primary PCI, since the presence of prior anemia
identified a subset of patients, characterized by advanced
age, higher comorbidities and serious coronary artery dis-
ease, at higher risk for intra ICCU mortality and compli-
cations. Moreover, the development of anemia during an
ICCU stay is common, and is associated with a higher
mortality rate and incidence of complications in respect to
patients who maintain normal Hb values.
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Introduction
Recent guidelines on non-ST-elevation myocardial infarc-
tion (NSTEMI) [1] report that anemia is associated with a
worse prognosis in patients with acute coronary syndromes
(ACS). In these patients, a low admission hemoglobin (Hb)
is an independent marker of the risk of ischemic and
bleeding events at 30 days, and it should be taken into
consideration in assessing the initial risk.
Existing data on the impact of anemia in patients with
ST-elevation myocardial infarction (STEMI) treated with
primary percutaneous coronary intervention (PCI) are
inconsistent and lead to controversy [2–6].
The present investigation, performed in 1,122 consecu-
tive STEMI patients treated with primary PCI, was aimed
at evaluating: (1) the prevalence of a pre-existing anemia
(prior anemia), and its prognostic significance in the short
term; and (2) the prevalence of anemia developing during
an intensive cardiac care unit (ICCU) stay (new anemia),
and its impact on early mortality.
Methods
The clinical, angiographic, and in-hospital outcomes of
1,122 consecutive patients with STEMI (within 12 h from
symptoms’ onset), who were admitted to our ICCU from
1 January 2004 to 31 December 2009, were prospectively
stored in a dedicated database. In our hospital, in Florence,
the reperfusion strategy of STEMI patients is represented
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by primary PCI [7]. STEMI patients are first evaluated by
the medical emergency system staff in the pre hospital
setting, and then directly admitted to the catheterization
laboratory or transferred to it after a rapid stabilization in
the emergency department (ED) After primary PCI, they
are admitted to our ICCU.
The diagnosis of STEMI was based on the criteria of the
American College of Cardiology/American Heart Associ-
ation [8].
Coronary angiography and angioplasty were performed
using standard techniques, by percutaneous femoral or
radial artery approach. Before PCI, a 70 UI/kg i.v. bolus of
unfractionated heparin was administered (bolus max
5000 UI), followed by additional weight-adjusted doses, in
order to maintain an activated clotting time C250 s
throughout the procedure. All patients were given 500 mg
of aspirin and 300 or 600 mg clopidogrel. Abciximab was
administered according to the operator’s judgment.
A successful PCI was defined as an infarct artery ste-
nosis \20% associated with thrombolysis in myocardial
infarction (TIMI) grade 3 flow. Failure PCI was defined as
resulting in TIMI grade 0 to 2 flow, regardless of the
residual stenosis [9].
Anemia was defined in accordance with the World Health
Organization (WHO) definitions (hemoglobin \13 g/dl in
men and \12 g/dl in women) [10]. ‘‘New anemia’’ was
defined as anemia (according WHO definition) developing
during an ICCU stay.
Comorbidities were defined as follows [4]: prior stroke
or transient ischemic cerebral attack, history of peripheral
vascular disease, history of gastrointestinal bleeding, and
history of genitourinary bleeding.
Major bleeding was defined according to the ACUITY
criteria [11]: intracranial or intraocular bleeding; access
site hemorrhage requiring intervention; 5 cm or more
diameter hematoma; clinically overt blood loss with
hemoglobin decrease C3 g/dl; any hemoglobin decrease
C4 g/dl or blood product transfusion.
On ICCU admission, blood samples were obtained for
hemochrome, cardiac biomarkers, glucose and serum cre-
atinine levels, high-sensitivity C-reactive protein (hs-CRP),
erythrocyte sedimentation rate (ESR), leukocyte and
platelet counts. As indicated in our ICCU protocol, cardiac
biomarkers, glucose, serum creatinine levels and hemo-
chrome were evaluated every 6 h for the first 12 h, and
every 8 h afterwards.
Estimated glomerular filtration rate (eGFR) was calcu-
lated according to the Levey modified MDRD formula
[12].
For the present analysis, the following hemoglobin values
were used: (1) Hb on ICCU admission; (2) nadir Hb (the
lowest hemoglobin value during ICCU stay); (3) delta Hb
(the difference between admission and nadir hemoglobin,
g/dl) and (4) the percentage of variation in respect to Hb on
admission (% delta Hb).
The study protocol was in accordance with the Decla-
ration of Helsinki and approved by the local ethics
committee.
Statistical analysis
The statistical analysis was performed using the SPSS
software package (version 11.5, SPSS Inc., Chicago, IL,
USA). Categorical variables are reported as frequencies
and percentages; continuous variables as median and 25th–
75th percentile. A statistical significance level (p) \0.05
was used. All hypothesis testings were two-tailed.
Descriptive analyses were conducted on the entire data set,
consistent of baseline demographic, clinical, laboratory and
angiographic variables, by means of Pearson v2 test (or
Fisher’s exact test, when needed) and Mann–Whitney
U test, as appropriate. We built a logistic regression model
using methods suggested by Hosmer and Lemeshow
[13].Variables thought to have clinical importance, and
those with p \ 0.05 in the univariable analysis, were
included in the logistic model (Outcome: in-ICCU mor-
tality; development of new anemia). The following base-
line clinical characteristics were considered in the model:
age, weight, smoking habits, comorbidities, renal failure,
prior infarction, prior PCI, Killip class on admission,
admission systolic blood pressure, admission Hb, nadir Hb,
% delta Hb, CPK, Tn I, peak glycemia, admission and peak
creatinine, ESR, coronary artery disease, PCI failure.
Results
Table 1 shows the baseline characteristics of all patients
included in the study, and the comparison of three sub-
groups: (1) those who showed anemia on ICCU admission
(‘‘prior anemia’’); (2) those who developed anemia during
the ICCU stay (‘‘new anemia’’); (3) those who maintained
normal Hb values during the ICCU stay (‘‘normal Hb’’). In
our series, 307 patients (27.4%) were anemic on admission
(prior anemia), while 525 patients (46.8%) developed
anemia during the ICCU stay (new anemia). Two hundred
and ninety patients maintained normal Hb values (25.8%)
(Fig. 1). Prior anemia was more frequent in females in
respect to patients with normal Hb (p \ 0.001). Patients
with prior anemia were older (p \ 0.001) and with a lower
BMI (p \ 0.001), more frequently never smokers (that is
patients who never smoked, p \ 0.001), with comorbidi-
ties (p = 0.043), renal failure (p \ 0.001), prior MI
(p \ 0.001) and prior PCI (p \ 0.001).
Figure 2 shows the percentages of patients with prior
anemia, new onset anemia and normal Hb values according
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to LVEF; no significant difference was observed among
subgroups.
As depicted in Table 2, patients with prior anemia
showed lower values of admission systolic blood pressure
(p = 0.004) and left ventricular ejection fraction (\0.001)
and a higher Killip class (p \ 0.001).
Laboratory data are shown in Table 3. Patients with
new anemia exhibited the highest values of peak Tn I
(p \ 0.001) and glycemia (p \ 0.001), while prior anemia
was associated with the lowest eGFR at admission
(p \ 0.001) and during the ICCU stay (p \ 0.001). Patients
with prior anemia showed highest values of ESR and the
highest percentage of positive CRP.
Angiographic data are shown in Table 4. Patients with
prior anemia showed a higher incidence of three-vessel
Prior anemia; 
27.4%
New anemia; 
46.8%
Normal Hb; 
25.8%
Fig. 1 Prevalence of prior anemia and new anemia in our population
Table 1 Baseline characteristics of patients included in the study
All patients,
n = 1,122
Prior anemia,
n = 307 (27.4%)
New anemia,
n = 525 (46.8%)
Normal Hb throughout
ICCU stay, n = 290 (25.8%)
p value
Females/males 293/829 (26.1/73.9%) 101/206 (32.9/67.1%) 142/383 (27.0/73.0%) 50/240 (17.2/82.8%) \0.001
Age (years) 67 (58–77) 75.0 (65.0–81.0)*, 66.0 (57.0–75.0)*,§ 61.5 (53.0–71.0),§ \0.001
Weight (kg) 75 (65–83) 70.0 (60.5–80.0)*, 75.0 (65.0–84.0)*,§ 78.0 (70.0–88.0),§ \0.001
BMI (kg/m2) 26.0 (23.7–28.1) 24.8 (22.8–27.2)*, 26.1 (24.1–28.2)* 26.1 (24.6–28.7) \0.001
Hypertension 599 (53.4%) 170 (55.9%) 295 (56.5%) 134 (46.2%) 0.012
Diabetes 287 (25.6%) 112 (36.8%) 120 (23.0%) 55 (19.0%) 0.214
Dyslipidemia 404 (36.0%) 89 (29.3%)*, 202 (38.7%)*,§ 113 (39.0%)§, 0.013
Smoke 698 (62.2%) 160 (52.6%)*, 337 (64.4%)*,§ 201 (69.3%)§, \0.001
Renal failure 50 (4.5%) 31 (10.1%) 16 (3.0%)§ 3 (1.0%)§, \0.001
COPD 95 (8.5%) 33 (10.8%) 37 (7.0%) 25 (8.6%) 0.175
Comorbility 93 (8.3%) 35 (11.4%) 41 (7.8%) 17 (5.9%) 0.043
Previous AMI 160 (14.3%) 68 (22.2%)*, 57 (10.9%)* 35 (12.1%) \0.001
Previous angina 283 (25.2%) 69 (22.5%) 145 (27.6%) 69 (23.8%) 0.215
Previous PCI 154 (13.7%) 63 (20.6%)* 53 (10.1%)* 38 (13.1%) \0.001
Previous CABG 25 (2.2%) 12 (3.9%) 9 (1.7%) 4 (1.4%) 0.060
ICCU therapy
ASA 1083 (96.5%) 292 (95.4%) 510 (97.5%) 281 (97.2%) 0.229
Clopidogrel 1088 (97.0%) 285 (93.1%) 517 (98.9%) 286 (99.0%) \0.001
Ticlopidine 11 (0.1%) 8 (2.6%) 2 (0.4%) 1 (0.3%) 0.002 (F)
UFH 969 (86.4%) 269 (87.6%) 449 (85.6%) 251 (86.9%) 0.719
b-Blockers 932 (83.1%) 222 (72.7%) 456 (87.7%) 254 (87.9%) \0.001
ACE-I 1006 (89.7%) 251 (82.5%) 480 (92.5%) 275 (95.2%) \0.001
ARB 24 (2.1%) 9 (2.9%) 9 (1.6%) 6 (2.1%) 0.381(F)
Diuretics 820 (73.1%) 243 (79.6%) 386 (74.2%) 191 (66.1%) \0.001
Nitrates 577 (51.4%) 150 (49.0%) 275 (52.8%) 152 (52.6%) 0.543
Inotropes 168 (15.0%) 84 (27.4%) 70 (13.5%) 14 (4.9%) \0.001
ICCU intensive cardiac care unit, BMI body mass index, COPD chronic obstructive pulmonary disease, AMI acute myocardial infarction,
PCI percutaneous coronary intervention, CABG coronary artery by-pass graft, UFH unfractioned heparin, ACE-I angiotensin converting enzyme
inhibitors, ARB angiotensin receptor blockers, F Fisher’s exact test
* p \ 0.05 prior anemia versus new anemia
 p \ 0.05 prior anemia versus normal Hb throughout ICU stay
§ p \ 0.05 new anemia versus normal Hb throughout ICU stay
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coronary artery disease (p \ 0.001) and PCI failure
(p \ 0.001) while stent implantation and abciximab use
were less frequent in these patients (p \ 0.001). Major
bleeding and blood transfusions were more frequent in
prior anemia (p \ 0.001 and p \ 0.001, respectively).
Patients with prior anemia showed the highest intra-ICCU
mortality (10.7%; p \ 0.001) while patients who main-
tained normal Hb values showed the lowest mortality
(1.7%). Patients with new anemia exhibited intermediate
values of early mortality (2.9%).
Cardiogenic shock was the cause of death in the 90.6%
(48/53), septic shock in 4/53 (7.5%) and ictus in one
patient.
At logistic regression analysis the following variables
were independent predictors for intra-ICCU mortality: age
(OR 1.04; 95% CI 1.01–1.08; p \ 0.025); prior anemia
(OR 2.12; 95% CI 1.21–3.70, p = 0.009, even when cor-
rected for weight), ejection fraction (OR 0.93; 95% CI
0.90–0.96 p \ 0.001) and eGFR (OR 0.98; 95% CI
0.97–1.00 p = 0.036).
At logistic regression analysis the following variables
were independent predictors for the development of new
anemia during the ICCU stay (when adjusted for BMI,
eGFR and abciximab use): age (OR 1.02; 95% CI
1.01–1.03; p = 0.009); peak Tn I (OR 1.01; 95% CI
1.00–1.03; p = 0.042); Killip class (OR 1.63; 95%
CI 1.17–2.27; p = 0.004).
Discussion
In ACS, the prevalence of anemia, defined according to the
WHO, shows a wide variation in literature data [14–20]. It is
reported to have a prevalence of 5–10% in patients with
NSTEMI ACS [21], of 43% in elderly STEMI patients [22]
and of 12.8% in acute myocardial infarction (AMI) [4]. In
80 Normal Hbp = 0.130
60
New anemia
Prior anemia
40%
20
0
LVEF <45% LVEF≥45%
Fig. 2 Percentages of patients with prior anemia, new onset anemia
and normal Hb values according to LVEF
Table 2 Clinical presentation
All patients,
n = 1,122
Prior anemia,
n = 307 (27.4%)
New anemia,
n = 525 (46.8%)
Normal Hb throughout
ICCU stay, n = 290 (25.8%)
p value
Admission heart rate (bpm) 77 (67–88) 77 (66–90) 78 (68–89) 76 (65–85) 0.169
Admission SBP (mmHg) 130 (115–145) 125 (110–145)*, 130 (115–145)* 130 (119–147) 0.004
ST decrease [50% 439 (62.4%) 106 (62.7%) 207 (61.6%) 126 (63.6%) 0.893
Killip class
I 896 (79.9%) 214 (69.7%) 414 (78.9%) 268 (92.4%) \0.001
II 100 (8.9%) 35 (11.4%) 52 (9.9%) 13 (4.5%)
III 35 (3.1%) 13 (4.2%) 18 (3.4%) 4 (1.4%)
IV 91 (8.1%) 45 (14.7%) 41 (7.8%) 5 (1.7%)
AMI location
Inferior 426 (38.0%) 132 (43.0%) 194 (37.0%) 100 (34.5%) 0.230
Lateral 91 (8.1%) 23 (7.5%) 46 (8.8%) 22 (7.6%)
Anterior 605 (53.9%) 152 (49.5%) 285 (54.3%) 168 (57.9%)
LVEF (%)
Mean 43.2 ± 10.1 41.4 ± 11.0 43.2 ± 9.9 44.9 ± 9.1 \0.001
Median 45 (35–50) 45 (35–50) 45 (35–50)§ 45 (40–52),§ 0.004
ICCU intensive cardiac care unit, SBP systolic arterial blood pressure, AMI acute myocardial infarction
* p \ 0.05 prior anemia versus new anemia
 p \ 0.05 prior anemia versus normal Hb throughout ICU stay
§ p \ 0.05 new anemia versus normal Hb throughout ICU stay
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our population, comprising unselected consecutive STEMI
patients submitted to PCI, the prevalence of anemia was
27.4%, a value comparable with that reported by Archbold
et al. [21] (22.4%) and by Valeur et al. [23] (25%).
The impact of anemia on mortality in AMI patients is
still under debate [24, 25]. In a study [2] involving 39,922
ACS patients, anemia is a powerful and independent pre-
dictor of major cardiovascular events in a 30-day follow-
up, especially in STEMI patients. Nikolsky et al. [4] report
that, in patients with AMI submitted to coronary angio-
plasty, baseline anemia is strongly associated with adverse
outcomes and increased mortality (30 days, 6 months and
1 year). On the other hand, Al Falluji et al. [3] document
that anemia on admission has no significant direct effect on
1-year mortality, and that the higher unadjusted mortality
observed among patients with AMI and anemia is probably
the result of older age, higher comorbidity and more left
ventricular dysfunction.
There are two main findings of the present investigation,
performed in a large series of consecutive STEMI patients
submitted to PCI.
Firstly, prior anemia, which is observed in about one-
third of our population, represents an independent risk
factor for intra-ICCU mortality, mainly because it is
associated with advanced age, comorbidities (such as renal
disease and previous heart disease) and complications
(such as PCI failure and major bleedings). In our series,
renal disease was more frequent in patients with a prior
anemia, and renal dysfunction is known to be an adverse
prognostic marker in patients with ischemic heart disease
[26], in particular in those who are anemic [27]. In the
acute phase, the presence of a prior anemia was also
associated with a higher incidence of PCI failure, thus
confirming previous investigations, reporting a higher
occurrence of complications in anemic patients after PCI
[27, 28]. In fact, in patients submitted to elective PCI,
anemia has a role in nonfatal thrombotic coronary events
and restenosis [28] and it is associated with higher short
term adverse procedural events. In our series, though the
use of abciximab was lower in patients with a prior anemia,
the incidence of major bleedings was higher in these
patients, in agreement with previous reports [4, 5, 19, 29].
Secondly, we documented that the development of a
new anemia during the ICCU stay is quite common,
involving about half of the patients; it is mainly related to
phlebotomy, periprocedural bleeding, and groin hematoma.
Advanced age and the extent of myocardial damage
(as indicated by peak Tn I and a higher Killip class) were
independent predictors for the development of a new ane-
mia. We observed, for the first time that a new anemia is
associated with a higher early mortality in respect to that
observed in patients who maintain normal Hb values.
The long-term prognostic significance of changes in
hemoglobin levels during hospital course was investigated
by Aronson et al. [6] in 1,390 survivors of AMI. The
authors report that anemia at discharge is a common find-
ing (36%), and associated with an increased long term
mortality.
In our series, the higher early mortality observed in
patients with a new anemia in respect to those with normal
Hb values can be related to several factors. Firstly, the
incidence of major bleeding (as well as blood transfusions)
Table 3 Laboratory data
All patients,
n = 1,122
Prior anemia,
n = 307 (27.4%)
New anemia,
n = 525 (46.8%)
Normal Hb throughout
ICCU stay, n = 290 (25.8%)
p value
Admission Hb (g/dl) 13.7 (12.5–14.6) 11.4 (10.4–12.3)*, 13.8 (13.3–14.5)*,§ 14.9 (14.2–15.7),§ \0.001
Nadir Hb (g/dl) 11.8 (10.4–12.9) 10.0 (8.7–11.1)*, 11.7 (10.8–12.4)*,§ 13.5 (13.1–14.0),§ \0.001
Delta Hb (g/dl) 1.7 (1.0–2.6) 1.2 (0.4–1.9)* 2.3 (1.6–3.1)*,§ 1.3 (0.7–2.0)§ \0.001
Delta Hb (% admission Hb) 12.7 (7.4–18.6) 10.1 (4.1–16.9)*, 16.3 (11.6–22.4)*,§ 8.8 (4.9–13.3),§ \0.001
Admission platelet count (91,000/ml) 213 (175–256) 212 (166–276) 219 (182–256)§ 206 (173–243)§ 0.067
Peak TnI (ng/ml) 82.4 (37.0–177.5) 74.5 (32.3–181.5)* 99.0 (46.6–190.0)*,§ 73.8 (31.5–150.5)§ \0.001
eGFR admission (ml/min/1.73 m2) 78.2 (62.9–94.2) 72.4 (45.3–87.8)*, 79.3 (65.2–95.3)*,§ 84.2 (68.7–99.1),§ \0.001
nadir eGFR (ml/min/1.73 m2) 70.9 (52.4–85.6) 58.2 (34.6–77.1)*, 72.2 (57.1–87.2)*,§ 75.7 (63.1–90.0),§ \0.001
Glycemia (mg/dl) 1.32 (1.12–1.72) 1.44 (1.20–2.06)*, 1.33 (1.12–1.66)§,* 1.24 (1.05–1.53)§, \0.001
ESR (mm/h) 25 (13–42) 32 (17–58)*, 25 (14–41)*,§ 18 (9–29),§ \0.001
Positive hs-CRP 470 (50.5%) 146 (58.9%) 227 (50.9%) 97 (41.1%) \0.001
ICCU intensive cardiac care unit, LVEF left ventricle ejection fraction, eGFR estimated glomerular fltration ratio, ESR erythrocyte sedimentation
rate hs-CRP high sensibility C-reactive protein
* p \ 0.05 prior anemia versus new anemia
 p \ 0.05 prior anemia versus normal Hb throughout ICU stay
§ p \ 0.05 new anemia versus normal Hb throughout ICU stay
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is higher in patients with a new anemia, though the use of
abciximab was lower in respect to patients with normal Hb
values. Secondly, the extent of myocardial injury is higher
in patients with a new anemia. It is conceivable that the
coexistance of a large infarct size and a newly developed
anemia may predispose to tissue hypoperfusion, and thus to
increased mortality.
The association between anemia and early mortality can
be related to several factors: anemia may cause catechol-
amine excess, increase myocardial oxygen demand by
necessitating a higher stroke volume and heart rate to
maintain adequate systemic oxygen delivery, and lead to
ischemia given restricted coronary flow. It may also pro-
mote the development of heart failure by causing adverse
left ventricular remodeling.
In conclusion, our data strengthens the prognostic role of
Hb values in STEMI patients submitted to primary PCI
since the presence of a prior anemia identifies a subset of
patients, characterized by advanced age, higher comor-
bidities and serious coronary artery disease, at higher risk
for intra ICCU mortality and complications. Moreover, the
development of anemia during the ICCU stay is common,
Table 4 Angiographic data and complications
All patients,
n = 1,122
Prior anemia,
n = 307 (27.4%)
New anemia,
n = 525 (46.8%)
Normal Hb throughout
ICCU stay, n = 290 (25.8%)
p value
Coronary artery disease
No disease 1 (0.1%) 1 (0.3%) 0 (0.0%) 0 (0.0%) \0.001
1 to vessel 438 (39.0%) 105 (34.2%) 197 (37.5%) 136 (46.9%)
2 to vessel 385 (34.3%) 96 (31.3%) 193 (36.8%) 96 (33.1%)
3 to vessel 298 (26.6%) 105 (34.2%) 135 (25.7%) 58 (20.0%)
Involvement of
CABG 16 (1.4%) 7 (2.3%) 5 (1.0%) 4 (1.4%) 0.297
Left main 83 (7.4%) 27 (8.9%) 36 (6.9%) 20 (6.9%) 0.532
TIMI flow pre-PCI
III 19 (1.7%) 6 (2.0%) 10 (1.9%) 3 (1.0%) 0.023
II 109 (9.7%) 25 (8.1%) 42 (8.0%) 42 (14.5%)
I 194 (17.3%) 55 (17.9%) 80 (15.2%) 59 (20.3%)
0 800 (71.3%) 221 (72.0%) 393 (74.9%) 186 (64.2%)
IRA
RCA 361 (32.2%) 111 (36.2%) 171 (32.6%) 79 (27.2%) 0.236
CX 145 (12.9%) 42 (13.7%) 61 (11.6%) 42 (14.5%)
DA 593 (52.9%) 147 (47.9%) 281 (53.5%) 165 (56.9%)
Left main 12 (1.1%) 3 (1.0%) 8 (1.5%) 1 (0.3%)
CABG 10 (0.9%) 3 (1.0%) 4 (0.8%) 3 (1.0%)
Stent implantation 996 (88.8%) 254 (83.0%)*, 478 (91.0%)*,§ 264 (91.3%),§ \0.001
Abciximab 546 (48.6%) 105 (34.2%)*, 275 (52.4%)*,§ 166 (57.2%),§ \0.001
TIMI flow post-PCI
III 1056 (94.1%) 272 (88.5%) 499 (95.0%) 285 (97.6%) \0.001
II 42 (3.7%) 18 (5.9%)*, 21 (4.0%)*,§ 3 (1.0%),§
I 11 (1.0%) 6 (2.0%) 3 (0.5%) 2 (0.7%)
0 13 (1.2%) 8 (2.6%) 3 (0.5%) 2 (0.7%)
PCI failure 66 (5.9%) 32 (10.4%) 27 (5.2%) 7 (2.4%) \0.001
Major bleeding 134 (11.9%) 53 (17.3%) 78 (14.9%)§ 3 (1.0%),§ \0.001
Blood transfusion 71 (6.3%) 52 (16.9%)*, 18 (3.4%)*,§ 1 (0.3%),§ \0.001
Dead patients 53 (4.7%) 33 (10.7%)*, 15 (2.9%)*,§ 5 (1.7%),§ \0.001
ICCU intensive cardiac care unit, CABG coronary artery by-pass graft, PCI percutaneous coronary intervention, IRA infarct related artery,
RCA right coronary artery, CX circumflex coronary artery, DA descending anterior coronary artery
* p \ 0.05 prior anemia versus new anemia
 p \ 0.05 prior anemia versus normal Hb throughout ICU stay
§ p \ 0.05 new anemia versus normal Hb throughout ICU stay
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and is associated with a higher mortality rate and incidence
of complications in respect to patients who maintain
normal Hb values.
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